中国慢性髓性白血病伊马替尼耐药或不耐受患者采用达沙替尼治疗的临床疗效及安全性研究

摘要

ObjectiveTo research application value by dasatinib in the treatment of imatinib resistance or intolerance in chronic myelogenous leukemia(CML).MethodsA total of 90 CML patients with imatinib resistance or intolerance were divided by different medication into control group (nilotinib for treatment) and observation group (dasatinib for treatment), with 45 cases in each group. Observation was made on complete cytogenetic remission (CCyR), complete hematologic remission (CHR), main molecular biology remission (MMR)/complete molecular biology remission (CMR) rates and incidence of adverse reactions in the two groups.Results Comparing with the control group, the observation group had higher CCyR remission rate in chronic period and higher CHR, MMR/CMR rates in acceleration period. The observation group had lower mortality rate and progression rate in in acceleration period and less adverse reaction in treatment. The differences all had statistical significance (P<0.05).ConclusionDasatinib provides remarkable effect and tolerance in treating patients with imatinib resistance or intolerance in chronic myelogenous leukemia. It is worth promoting.%目的：研究达沙替尼在慢性髓性白血病(CML)伊马替尼耐药或不耐受患者中的应用价值。方法根据用药不同将90例CML伊马替尼耐药或不耐受患者随机分为对照组(尼洛替尼治疗)和观察组(达沙替尼治疗)，各45例。观察两组完全细胞遗传学(CCyR)、完全血液学(CHR)、主要生物分子学(MMR)/完全分子生物学(CMR)缓解率及不良反应发生率。结果与对照组比较，观察组慢性期患者CCyR缓解率及加速期患者CHR、MMR/CMR缓解率均更高，加速期死亡率及进展率更低，治疗期间不良反应更少，差异均有统计学意义(P<0.05)。结论达沙替尼治疗慢性髓性白血病伊马替尼耐药或不耐受患者的临床疗效优，患者更耐受，值得推广。